A
11.24
-0.11 (-0.97%)
| Previous Close | 11.35 |
| Open | 11.27 |
| Volume | 2,373,454 |
| Avg. Volume (3M) | 2,103,609 |
| Market Cap | 1,543,442,944 |
| Price / Earnings (Forward) | 111.11 |
| Price / Sales | 639.08 |
| Price / Book | 33.61 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -6,456.48% |
| Diluted EPS (TTM) | -5.15 |
| Quarterly Revenue Growth (YOY) | -29.60% |
| Total Debt/Equity (MRQ) | 1,555.14% |
| Current Ratio (MRQ) | 6.09 |
| Operating Cash Flow (TTM) | -491.28 M |
| Levered Free Cash Flow (TTM) | -382.80 M |
| Return on Assets (TTM) | -47.71% |
| Return on Equity (TTM) | -565.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arrowhead Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | 5.0 |
| Insider Activity | -3.5 |
| Price Volatility | 3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.10 |
|
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.09% |
| % Held by Institutions | 74.63% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avoro Capital Advisors Llc | 31 Dec 2024 | 11,111,111 |
| Slate Path Capital Lp | 31 Dec 2024 | 5,232,000 |
| Siren, L.L.C. | 31 Dec 2024 | 2,901,681 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 611.74%) | Buy |
| Median | 51.00 (353.74%) | |
| Low | 38.00 (B. Riley Securities, 238.08%) | Buy |
| Average | 55.00 (389.32%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 19.08 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B. Riley Securities | 14 Feb 2025 | 38.00 (238.08%) | Buy | 19.95 |
| HC Wainwright & Co. | 12 Feb 2025 | 80.00 (611.74%) | Buy | 18.57 |
| 23 Jan 2025 | 80.00 (611.74%) | Buy | 21.53 | |
| Chardan Capital | 11 Feb 2025 | 60.00 (433.81%) | Buy | 18.89 |
| RBC Capital | 11 Feb 2025 | 42.00 (273.67%) | Buy | 18.89 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ANZALONE CHRISTOPHER RICHARD | - | 11.57 | -141,122 | -1,630,232 |
| Aggregate Net Quantity | -141,122 | |||
| Aggregate Net Value ($) | -1,630,232 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 11.57 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ANZALONE CHRISTOPHER RICHARD | Officer | 11 Apr 2025 | Sell (-) | 50,800 | 11.79 | 598,932 |
| ANZALONE CHRISTOPHER RICHARD | Officer | 10 Apr 2025 | Sell (-) | 50,000 | 11.11 | 555,500 |
| ANZALONE CHRISTOPHER RICHARD | Officer | 09 Apr 2025 | Sell (-) | 40,322 | 11.80 | 475,800 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |